Home / Pipeline

The GLP-1 Pipeline.

Every next-generation weight-loss drug in development — mechanism, trial stage, and expected FDA timing. Updated weekly.

DrugDeveloperMechanismFormPhaseExpected FDAHeadline result
RetatrutideEli LillyTriple agonist (GLP-1 / GIP / glucagon)InjectionPhase 32026–2027~24% weight loss at 48 weeks in Phase 2
OrforglipronEli LillyOral GLP-1 small moleculePillPhase 32026~14.7% weight loss at 72 weeks (ATTAIN-1)
CagriSemaNovo NordiskAmylin (cagrilintide) + semaglutideInjectionPhase 32026~22% weight loss at 68 weeks (REDEFINE-1)
MariTideAmgenGLP-1 + GIP antagonist, monthly injectionInjectionPhase 32027~20% weight loss at 52 weeks (Phase 2)
SurvodutideBoehringer / ZealandDual GLP-1 / glucagon agonistInjectionPhase 32027~19% weight loss at 46 weeks

Why this matters

The GLP-1 class is still early. Today's leaders ([Wegovy](/drugs/wegovy), [Zepbound](/drugs/zepbound)) will be followed within 12–24 months by drugs that are meaningfully more effective, easier to take, or dramatically cheaper. Knowing what's coming helps you plan — when to start treatment, when to switch, and whether to wait.

The four pipeline drugs worth watching

Retatrutide (Eli Lilly) — the potential new leader

Retatrutide is a triple agonist targeting the GLP-1, GIP, and glucagon receptors simultaneously. The addition of glucagon activity to the GLP-1/GIP combination already in tirzepatide produces substantially greater weight loss in early trials — approximately 24% mean weight loss at 48 weeks in Phase 2, with the curve not yet flat at end-of-trial. If Phase 3 holds, retatrutide would be the most effective weight-loss drug ever approved by the FDA. Expected approval 2026–2027.

What to watch for: cardiovascular outcomes data (Lilly has not released CV-specific trials yet), glucagon-related effects on glucose regulation in diabetics, and real-world tolerability at the higher efficacy dose tiers.

Orforglipron (Eli Lilly) — the oral breakthrough

Orforglipron is the first non-peptide, small-molecule oral GLP-1 to reach late-stage development. Small molecules can be manufactured at conventional drug costs — potentially 5–10x cheaper than injectable peptide GLP-1s. That manufacturing shift alone could reshape the obesity drug market.

Phase 3 results from ATTAIN-1 showed approximately 14.7% weight loss at 72 weeks — comparable to injectable Wegovy, but without needles and with far broader manufacturing scalability. Expected FDA filing 2026, approval 2026 or early 2027.

CagriSema (Novo Nordisk) — the semaglutide upgrade

CagriSema combines cagrilintide (a long-acting amylin analog) with semaglutide. Amylin is a gut hormone that works complementarily to GLP-1 on satiety. REDEFINE-1 showed approximately 22% weight loss at 68 weeks — putting CagriSema in tirzepatide's efficacy range and giving Novo its first credible answer to Lilly's lead.

Expected FDA filing 2026. CagriSema is likely to be priced and positioned similarly to Wegovy, which means existing Wegovy coverage should mostly transfer.

MariTide (Amgen) — the monthly option

MariTide is a GLP-1 / GIP antagonist formulated for monthly subcutaneous injection — the first GLP-1 in late-stage development with dosing less frequent than weekly. Phase 2 showed ~20% weight loss at 52 weeks.

If Phase 3 confirms safety and efficacy, monthly dosing could fundamentally change adherence in the class. Patients who struggle with weekly injection discipline would have a major new option. Expected FDA approval 2027.

What to do with this information

Don't wait. Pipeline drugs are 12–24 months out from availability. The time you spend at a higher weight typically costs more in cumulative comorbidity risk than the potential benefit of waiting for a marginally better drug. Starting now on [Zepbound](/drugs/zepbound) or [Wegovy](/drugs/wegovy) and [switching](/guides/how-to-switch-glp1-drugs) when pipeline drugs approve is the standard playbook.

Plan for the switch. If you're on Wegovy today and orforglipron approves next year, your prescriber can transition you with no washout required. The switching guide walks through the common transitions.

Watch for cost shifts. Orforglipron's small- molecule manufacturing could substantially lower the floor for GLP-1 pricing. If it launches at significantly below current injectable cash prices, cash-pay patients may have much better options in 12 months than today.

Frequently asked questions

What is the next GLP-1 drug after Zepbound?
Retatrutide (Eli Lilly) is the most anticipated next-generation GLP-1. It's a triple agonist targeting GLP-1, GIP, and glucagon receptors simultaneously, and produced about 24% mean weight loss at 48 weeks in Phase 2 — potentially the most effective obesity drug ever developed. Phase 3 trials are ongoing; expected FDA approval is 2026–2027.
When will oral GLP-1s match Zepbound's efficacy?
Probably 2026–2027. Orforglipron (Eli Lilly) is a non-peptide oral small molecule GLP-1 that produced ~14.7% weight loss at 72 weeks in Phase 3 (ATTAIN-1). Higher doses and combinations in development could close the efficacy gap with tirzepatide. Once approved, oral GLP-1s could unlock dramatically lower manufacturing costs and broader access.
What is CagriSema?
CagriSema is Novo Nordisk's combination of cagrilintide (an amylin analog) with semaglutide. REDEFINE-1 showed approximately 22% weight loss at 68 weeks — putting it in the same efficacy range as tirzepatide. It's Novo's answer to Eli Lilly's Zepbound lead. Expected FDA filing 2026.
What is MariTide?
MariTide (Amgen) is a GLP-1 / GIP antagonist with a differentiated profile: monthly dosing instead of weekly. Phase 2 showed about 20% weight loss at 52 weeks. If Phase 3 confirms efficacy and safety, monthly dosing could fundamentally change patient adherence in the category. Expected FDA approval 2027.
Should I wait for a pipeline drug or start treatment now?
Almost always start now. The time spent at a higher weight typically costs more in cumulative comorbidity risk and quality of life than the potential benefit of waiting 12-24 months for a marginally better drug. Switching to a new GLP-1 when it becomes available is typically straightforward — see our guide on how to switch between GLP-1 drugs.
Will any pipeline drug be cheaper than current GLP-1s?
Orforglipron has the strongest cost-reduction potential because it's a non-peptide small molecule that can be manufactured at conventional small-molecule drug costs — potentially 5-10x cheaper than injectable peptides. Whether that pricing passes through to patients depends on payer dynamics post-approval.

Want pipeline updates when they break? Subscribe to The Sherpa Weekly.

Last reviewed April 2026. Pipeline drug status changes frequently as trials complete. We re-verify weekly.